It's a hard blow for Orphazyme that the US Food and Drug Administration (FDA) has rejected the biotech firm's main candidate arimoclomol for the treatment of the metabolic disease Niemann-Pick type C (NPC).
In connection with the verdict, the biotech company communicates that it is downgrading its guidance for 2021, and the company CEO says that corporate costs will be reviewed.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
GN Hearing top exec stops after 17 years – replacement found within own ranks
The CEO of hearing company GN Hearing's US subsidiary Audigy is now retiring after 17 years in the hot seat. The company, which was acquired by GN Hearing in 2016, has found his replacement within own ranks.
Pharma industry is discretely working against a global tax agreement
The pharmaceutical industry is fighting against a threat to companies' bottom lines: a global agreement which will harmonize corporation tax.
Pfizer upgrades guidance for sales of covid-19 vaccine
The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.
Astrazeneca shot shows no increased clot risk after two doses
Blot clots are not more likely after second Astrazeneca jab, data published in The Lancet suggests.
Boston Scientific reports significant growth in endoscopy business – grows 54 percent
In Q2, medtech firm Boston Scientific sold significantly more endoscopy products, which is the core business area of Danish company Ambu. The US giant is upgrading its guidance for the whole year.
Manager/Associate Director Regulatory Affairs - Ascendis Pharma 
Analytical Coordinator - Symphogen 
(Senior) Regulatory Science Specialist - IWA Consulting 
Research Scientist, Immunology/Translational Research - ALK 
Employee for regulatory department 
Senior Clinical Data Manager - Vaccibody 
Quality Manager, Americhem 
Associate Medical Director, Translational Medicine - Y-mAbs Therapeutics 
Toxicologist - Lundbeck 
Business developer within Medical Diagnostics 
Health sector expert at the Danish Embassy in Berlin